Abstract
We sought to evaluate the angiographic efficacy and clinical safety and effectiveness of the combined sirolimus-eluting CD34 antibody coated Combo stent (OrbusNeich Medical, Ft. Lauderdale, Florida) in a randomized trial designed to enable its approval by the China Food and Drug Administration.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
